Our biopharmaceutical businesses include our Pfizer Innovative Health , Pfizer Essential Health, Vaccines and Oncology business.
These businesses are generally responsible for late-stage clinical development of medicines that have advanced to at least phase 2b of clinical development, having achieved earlier stages of pre-identified safety and efficacy measures.
With each business focusing on global but specific areas of medicine and related-services, our unique structure allows us to be more responsive and flexible to the needs of our partners.
Pfizer Innovative Health
At Pfizer, putting the patient first drives our passion, inspires us to collaborate, and motivates us to create and innovate. For the newly formed Pfizer Innovative Health, this belief represents something even more: it defines how we organize ourselves and evaluate performance. Most of all, it holds us accountable for creating a healthier world
Pfizer Innovative Health
As a combined group – encompassing Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines – Pfizer Innovative Health is committed to changing the outcome of chronic conditions and devastating diseases around the world. We are focused on improving health with our innovative products and vaccines — from prevention to treatment to wellness — at every stage of life in communities across the globe. Everything we do is to ensure that people have a chance to live longer, get stronger, and lead more vibrant lives.
See contact list Pfizer Innovative Health
Pfizer's Vaccines business is one of the industry’s largest, with more than $4 billion in global revenue.
Pfizer's Vaccines business unit is one of the industry’s largest, with more than $4 billion in global revenue. The unit is responsible for the commercial development of a robust and active pipeline in both prophylactic and therapeutic vaccines.
See contact list for Vaccines
Pfizer Oncology is striving to cure or control cancer with innovative medicines.
Pfizer Oncology is striving to cure or control cancer with breakthrough medicines. Compounds under evaluation are across four scientific platforms — anti-angiogenesis, signal transduction, cell cycle, and metabolism — and multiple tumor types. Guided by the principles of precision medicine and working collaboratively with academic institutions, individual researchers, cooperative research groups, governments, licensing partners, and other partners, we aim to deliver the right drug at the right time for each patient.
Oncology is a core area of research focus for Pfizer. Our Oncology Research Unit and Business Unit work in seamless partnership, with a mutual commitment to delivering highly innovative and commercially viable cancer therapies. In order to fulfill this commitment, we are continuously managing and refining our dynamic portfolio, which includes deciding which compounds to develop internally and which may be candidates for continued development through partnerships. At the same time, we are looking to complement our internal portfolio with compounds in early clinical development, those that have achieved proof of concept in randomized controlled multicenter phase 2 trials and phase 3 programs. We are seeking greater depth and breadth in key disease areas in our late-stage portfolio — renal cell carcinoma, lung cancer, hematologic malignancies, and breast cancer — while also looking to develop breakthrough medicines in other areas of unmet need. In addition, our Oncology Research Unit is focused in established areas such as cell signaling, and emerging areas of cancer biology, including tumor metabolism, epigenetics and antibody-drug conjugates (ADCs), a highly promising therapeutic modality that provides targeted delivery of an antibody drug linked to chemotherapy.
Areas of Interest
Late-stage assets in phase 2 and phase 3 (in randomized multi-center controlled clinical trials)
Highly differentiated assets which raise standard of care via clinically meaningful improvement in efficacy and/or safety
Focus on assets which fit a precision medicine strategy
Programs which include biomarkers that enable asset to provide significant benefit to targeted patient subset
Tumor areas of interest: Hematology, Lung, Breast, Renal Cell Carcinoma (Kidney)
Currently excluding cytotoxics, radiotherapies, supportive care and devices
Pfizer Essential Health
At Pfizer Essential Health we combine our history of industry leadership, comprehensive knowledge of global healthcare markets, and vast portfolio of trusted, quality medicines to benefit patients around the world at virtually every stage of life.
Pfizer Essential Health
Pfizer Essential Health is:
The number one non-viral anti-infective company; Number one in total biosimilar sales;The leading company in global off-patent sterile injectables; A leader in emerging markets
Pfizer Essential Health’s BD areas of focus include:
Opportunities in the Hospital Channel, including sterile injectables The therapeutic areas of Anti-infectives, Women’s Health and Neurology Biosimilars Emerging Markets Branded Products
Our strengths are what make us unique:
Depth & breadth of knowledge base We combine a history of trust and leadership in the industry with broad capabilities to anticipate patient and customer needs.
A vast portfolio of quality medicines
More than 600 medicines, delivered through a reliable and sustainable supply chain, serve patients at virtually every stage of life.
Direct global impact
Our global reach in 160-plus countries uniquely positions us to have a truly meaningful impact on patients’ lives.
See contact list for Pfizer Essential Health